Literature DB >> 19342596

Amplification of coronary arteriogenic capacity of multipotent stromal cells by epidermal growth factor.

Souad Belmadani1, Khalid Matrougui, Chris Kolz, Yuh Fen Pung, Desiree Palen, Darwin J Prockop, William M Chilian.   

Abstract

OBJECTIVE: We determined whether increasing adherence of multipotent stromal cells (MSCs) would amplify their effects on coronary collateral growth (CCG). METHODS AND
RESULTS: Adhesion was established in cultured coronary endothelials cells (CECs) or MSCs treated with epidermal growth factor (EGF). EGF increased MSCs adhesion to CECs, and increased intercellular adhesion molecule (ICAM-1) or vascular cell adhesion molecule (VCAM-1) expression. Increased adherence was blocked by EGF receptor antagonism or antibodies to the adhesion molecules. To determine whether adherent MSCs, treated with EGF, would augment CCG, repetitive episodes of myocardial ischemia (RI) were introduced and CCG was measured from the ratio of collateral-dependent (CZ) and normal zone (NZ) flows. CZ/NZ was increased by MSCs without treatment versus RI-control and was further increased by EGF-treated MSCs. EGF-treated MSCs significantly improved myocardial function versus RI or RI+MSCs demonstrating that the increase in collateral flow was functionally significant. Engraftment of MSCs into myocardium was also increased by EGF treatment.
CONCLUSIONS: These results reveal the importance of EGF in MSCs adhesion to endothelium and suggest that MSCs may be effective therapies for the stimulation of coronary collateral growth when interventions are used to increase their adhesion and homing (in vitro EGF treatment) to the jeopardized myocardium.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19342596      PMCID: PMC2796538          DOI: 10.1161/ATVBAHA.109.186189

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  41 in total

Review 1.  Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views.

Authors:  Donald G Phinney; Darwin J Prockop
Journal:  Stem Cells       Date:  2007-09-27       Impact factor: 6.277

Review 2.  The epidermal growth factor receptor and its inhibition in cancer therapy.

Authors:  J R Woodburn
Journal:  Pharmacol Ther       Date:  1999 May-Jun       Impact factor: 12.310

3.  Vascular endothelial growth factor induces heparin-binding epidermal growth factor-like growth factor in vascular endothelial cells.

Authors:  B M Arkonac; L C Foster; N E Sibinga; C Patterson; K Lai; J C Tsai; M E Lee; M A Perrella; E Haber
Journal:  J Biol Chem       Date:  1998-02-20       Impact factor: 5.157

4.  Intercellular communication between vascular smooth muscle and endothelial cells mediated by heparin-binding epidermal growth factor-like growth factor and vascular endothelial growth factor.

Authors:  R Abramovitch; M Neeman; R Reich; I Stein; E Keshet; J Abraham; A Solomon; M Marikovsky
Journal:  FEBS Lett       Date:  1998-04-03       Impact factor: 4.124

5.  Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion.

Authors:  Junming Tang; Qiyang Xie; Guodong Pan; Jianing Wang; Mingjiang Wang
Journal:  Eur J Cardiothorac Surg       Date:  2006-07-10       Impact factor: 4.191

6.  Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation.

Authors:  S Fujiyama; H Matsubara; Y Nozawa; K Maruyama; Y Mori; Y Tsutsumi; H Masaki; Y Uchiyama; Y Koyama; A Nose; O Iba; E Tateishi; N Ogata; N Jyo; S Higashiyama; T Iwasaka
Journal:  Circ Res       Date:  2001-01-19       Impact factor: 17.367

7.  Epidermal growth factor induces CD44 gene expression through a novel regulatory element in mouse fibroblasts.

Authors:  M Zhang; M H Wang; R K Singh; A Wells; G P Siegal
Journal:  J Biol Chem       Date:  1997-05-30       Impact factor: 5.157

Review 8.  Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary.

Authors:  M Simons; R O Bonow; N A Chronos; D J Cohen; F J Giordano; H K Hammond; R J Laham; W Li; M Pike; F W Sellke; T J Stegmann; J E Udelson; T K Rosengart
Journal:  Circulation       Date:  2000-09-12       Impact factor: 29.690

9.  Bone marrow cells regenerate infarcted myocardium.

Authors:  D Orlic; J Kajstura; S Chimenti; I Jakoniuk; S M Anderson; B Li; J Pickel; R McKay; B Nadal-Ginard; D M Bodine; A Leri; P Anversa
Journal:  Nature       Date:  2001-04-05       Impact factor: 49.962

10.  Lipopolysaccharide induces VCAM-1 expression and neutrophil adhesion to human tracheal smooth muscle cells: involvement of Src/EGFR/PI3-K/Akt pathway.

Authors:  Wei-Ning Lin; Shue-Fen Luo; Chou-Bing Wu; Chih-Chung Lin; Chuen-Mao Yang
Journal:  Toxicol Appl Pharmacol       Date:  2007-12-08       Impact factor: 4.219

View more
  15 in total

1.  Chronic inhibition of epidermal growth factor receptor tyrosine kinase and extracellular signal-regulated kinases 1 and 2 (ERK1/2) augments vascular response to limb ischemia in type 2 diabetic mice.

Authors:  Soo-Kyoung Choi; Maria Galán; Megan Partyka; Mohamed Trebak; Souad Belmadani; Khalid Matrougui
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

2.  Sodium nitrite therapy rescues ischemia-induced neovascularization and blood flow recovery in hypertension.

Authors:  Ali Amin; Soo-Kyoung Choi; Yehia Osman-Elazeik; Nariman K Badr El-Din; Christopher G Kevil; Louis G Navar; Philip Kadowitz; Mohamed Trebak; Khalid Matrougui
Journal:  Pflugers Arch       Date:  2012-10-07       Impact factor: 3.657

3.  Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice.

Authors:  Ali H Amin; Zakaria Y Abd Elmageed; Devika Nair; Megan I Partyka; Philip J Kadowitz; Souad Belmadani; Khalid Matrougui
Journal:  Lab Invest       Date:  2010-05-03       Impact factor: 5.662

Review 4.  Coronary collateral growth--back to the future.

Authors:  William M Chilian; Marc S Penn; Yuh Fen Pung; Feng Dong; Maritza Mayorga; Vahagn Ohanyan; Suzanna Logan; Liya Yin
Journal:  J Mol Cell Cardiol       Date:  2011-12-19       Impact factor: 5.000

5.  Chronic inhibition of endoplasmic reticulum stress and inflammation prevents ischaemia-induced vascular pathology in type II diabetic mice.

Authors:  Ali Amin; Soo-kyoung Choi; Maria Galan; Modar Kassan; Megan Partyka; Philip Kadowitz; Daniel Henrion; Mohamed Trebak; Souad Belmadani; Khalid Matrougui
Journal:  J Pathol       Date:  2012-02-17       Impact factor: 7.996

6.  Tumor necrosis factor inhibition increases the revascularization of ischemic hind-limbs in diabetic mice.

Authors:  Adel M A Assiri; Hatim A El-Baz; Ali H Amin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-05-31       Impact factor: 3.000

7.  Capillary arterialization requires the bone-marrow-derived cell (BMC)-specific expression of chemokine (C-C motif) receptor-2, but BMCs do not transdifferentiate into microvascular smooth muscle.

Authors:  Meghan M Nickerson; Caitlin W Burke; Joshua K Meisner; Casey W Shuptrine; Ji Song; Richard J Price
Journal:  Angiogenesis       Date:  2009-09-24       Impact factor: 9.596

Review 8.  Diabetes and microvascular pathophysiology: role of epidermal growth factor receptor tyrosine kinase.

Authors:  Khalid Matrougui
Journal:  Diabetes Metab Res Rev       Date:  2010-01       Impact factor: 4.876

Review 9.  Epidermal growth factor, from gene organization to bedside.

Authors:  Fenghua Zeng; Raymond C Harris
Journal:  Semin Cell Dev Biol       Date:  2014-02-07       Impact factor: 7.727

10.  Bone marrow-derived cell-specific chemokine (C-C motif) receptor-2 expression is required for arteriolar remodeling.

Authors:  Meghan M Nickerson; Ji Song; Joshua K Meisner; Sameer Bajikar; Caitlin W Burke; Casey W Shuptrine; Gary K Owens; Thomas C Skalak; Richard J Price
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-09-04       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.